Tucidinostat
产品说明书
 |
同义名 : | Chidamide;HBI-8000;CS 055 |
| CAS号 : | 1616493-44-7 | |
| 货号 : | A617381 | |
| 分子式 : | C22H19FN4O2 | |
| 纯度 : | 99%+ | |
| 分子量 : | 390.41 | |
| MDL号 : | MFCD28100259 | |
| 存储条件： |
Pure form Keep in dark place,Inert atmosphere,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(128.07 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
PO 5%DMSO + 30%PEG400 + 5%tween80 + 60%Water 3 mg/mL clear |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC50s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02718066 | Melanoma Rena... 展开 >>l Cell Carcinoma Non-Small Cell Lung Cancer 收起 << | Phase 1 Phase 2 | Recruiting | January 2020 | United States, Arizona ... 展开 >> [Site 02] Mayo Clinic Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Thai Ho United States, California [Site 11] University of California, San Diego Medical Center Recruiting La Jolla, California, United States, 92037 Contact: Lyudmila Bazhenova United States, Florida [Site 01] Hematology - Oncology Associates of the Treasure Coast Recruiting Port Saint Lucie, Florida, United States, 34952 Contact: Heather Yeckes-Rodin [Site 09] H. Lee Moffitt Cancer Center and Research Institute, Inc. Recruiting Tampa, Florida, United States, 33612 Contact: Nikhil Khushalani United States, Maryland [Site 13] Frederick Memorial Hospital d/b/a James M Stockman Cancer Institute Recruiting Frederick, Maryland, United States, 21702 Contact: Elhamy Eskander United States, Texas [Site 12] University of Texas M.D. Anderson Cancer Center - Investigational Cancer Therapeutics Recruiting Houston, Texas, United States, 77030 Contact: Siqing Fu 收起 << |
| NCT03574402 | Carcinoma, Non-Small-Cell Lung | Phase 2 | Not yet recruiting | December 30, 2024 | - |
| NCT02697552 | Non-Hodgkin's Lymphoma | Phase 1 | Completed | - | Japan ... 展开 >> Nagoya City University Hospital Aichi, Japan Fukuoka University Hospital Fukuoka, Japan NHO Kyushu Cancer Center Fukuoka, Japan Kagoshima University Medical and Dental Hospital Kagoshima, Japan Tokai University Hospital Kanagawa, Japan NHO Kumamoto Medical Center Kumamoto, Japan NHO Nagasaki Medical Center Nagasaki, Japan National Cancer Center Hospital Tokyo, Japan 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.56mL 0.51mL 0.26mL |
12.81mL 2.56mL 1.28mL |
25.61mL 5.12mL 2.56mL |
